Boston Scientific Corporation
BSXLast close · Oct 16, 202644.39+0.25 (+0.57%)
Market cap$64.3B
15 firms' latest targets, last 90 days: median $57.00 ($48.00–$70.00), 28% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-14 | Truist | $51.00 | ▼ 18% | +15% |
| 2026-10-13 | Mizuho Securities | $55.00 | ▼ 21% | +24% |
| 2026-10-06 | Barclays | $48.00 | ▼ 46% | +8% |
| 2026-10-03 | Bernstein | $54.00 | ▼ 52% | +22% |
| 2026-09-23 | Wells Fargo | $48.00 | ▼ 4% | +8% |
| 2026-09-21 | Oppenheimer | $65.00 | ▼ 24% | +46% |
| 2026-09-09 | BTIG | $56.00 | ▼ 7% | +26% |
| 2026-07-30 | RBC Capital | $70.00 | ▼ 18% | +58% |
| 2026-07-30 | UBS | $67.00 | ▼ 9% | +51% |
| 2026-07-30 | Deutsche Bank | $60.00 | — | +35% |
| 2026-07-30 | Baird | $56.00 | ▼ 20% | +26% |
| 2026-07-30 | Canaccord Genuity | $66.00 | ▼ 6% | +49% |
| 2026-07-30 | Leerink Partners | $60.00 | ▼ 19% | +35% |
| 2026-07-30 | Raymond James | $57.00 | — | +28% |
| 2026-07-29 | Stifel | $60.00 | ▼ 8% | +35% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $14.2B | +12% | $1.07 | +138% | est. $14.1B+1% | est. $2.01 | 20 |
| 2024reported | $16.7B | +18% | $1.25 | +17% | est. $16.6B+1% | est. $2.47 | 19 |
| 2025reported | $20.1B | +20% | $1.94 | +55% | est. $20.1B+0% | est. $3.04 | 21 |
| 2026 | $21.2B | +6% | $3.25 | +7% | $20.9B–$21.7B | $3.18–$3.31 | 20 |
| 2027 | $22.2B | +5% | $3.39 | +4% | $21.8B–$23.1B | $3.22–$3.60 | 21 |
| 2028 | $23.7B | +7% | $3.74 | +10% | $22.9B–$24.8B | $3.58–$4.05 | 20 |
| 2029 | $25.7B | +9% | $4.12 | +10% | $25.1B–$26.8B | $4.00–$4.34 | 10 |
| 2030 | $27.8B | +8% | $4.52 | +10% | $27.2B–$29.0B | $4.39–$4.76 | 10 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.